[go: up one dir, main page]

AR065336A1 - Preparacion de fluidos biologicos viralmente inactivados que tienen alta actividad de alfa -2- antiplasmina - Google Patents

Preparacion de fluidos biologicos viralmente inactivados que tienen alta actividad de alfa -2- antiplasmina

Info

Publication number
AR065336A1
AR065336A1 ARP080100619A ARP080100619A AR065336A1 AR 065336 A1 AR065336 A1 AR 065336A1 AR P080100619 A ARP080100619 A AR P080100619A AR P080100619 A ARP080100619 A AR P080100619A AR 065336 A1 AR065336 A1 AR 065336A1
Authority
AR
Argentina
Prior art keywords
preparation
biological fluids
antiplasmine
virally inactivated
inactivated biological
Prior art date
Application number
ARP080100619A
Other languages
English (en)
Original Assignee
Res Foundation For Medical Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Foundation For Medical Dev filed Critical Res Foundation For Medical Dev
Publication of AR065336A1 publication Critical patent/AR065336A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61L2103/05—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se relaciona con el uso de polioxietileno (4-5) p-t-octil fenol (t-Oct-C6H4-(OCH2CH2)xOH, x = 5) o polioxietileno (20) sorbitano monooleato, en la inactivacion viral de solvente/detergente de fluidos biologicos, para la preparacion deun fluido biologico viralmente inactivado, que tiene un alto contenido de alfa 2-antiplasmina.
ARP080100619A 2007-02-14 2008-02-13 Preparacion de fluidos biologicos viralmente inactivados que tienen alta actividad de alfa -2- antiplasmina AR065336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290186A EP1964579A1 (en) 2007-02-14 2007-02-14 Preparation of virally inactivated biological fluids having high alpha-2-antiplasmin activity

Publications (1)

Publication Number Publication Date
AR065336A1 true AR065336A1 (es) 2009-06-03

Family

ID=37946226

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100619A AR065336A1 (es) 2007-02-14 2008-02-13 Preparacion de fluidos biologicos viralmente inactivados que tienen alta actividad de alfa -2- antiplasmina

Country Status (8)

Country Link
US (1) US20100167378A1 (es)
EP (2) EP1964579A1 (es)
CN (1) CN101674854A (es)
AR (1) AR065336A1 (es)
AU (1) AU2008214616A1 (es)
BR (1) BRPI0807775A2 (es)
WO (1) WO2008098979A1 (es)
ZA (1) ZA200905627B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH706420A1 (fr) * 2012-04-19 2013-10-31 Valerie Soulie Procédé d'inactivation virale d'un fluide biologique, dispositif et récipient pour la mise en œuvre d'un tel procédé.
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
US20180016548A1 (en) * 2016-07-14 2018-01-18 Northwestern University Acellular scaffolds for maturation of ipsc-hepatocytes
IT201600091964A1 (it) * 2016-09-13 2018-03-13 Kedrion Spa Processo per la purificazione del plasminogeno a partire da plasma umano.
JP7734197B2 (ja) * 2021-02-12 2025-09-04 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド 試料溶解試薬組成物ならびにその製造方法およびその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
EP1685852A1 (en) * 2005-02-01 2006-08-02 Fondation pour la Recherche Diagnostique Set of disposable bags for viral inactivation of biological fluids

Also Published As

Publication number Publication date
EP2125042A1 (en) 2009-12-02
CN101674854A (zh) 2010-03-17
US20100167378A1 (en) 2010-07-01
EP1964579A1 (en) 2008-09-03
BRPI0807775A2 (pt) 2014-06-24
AU2008214616A1 (en) 2008-08-21
ZA200905627B (en) 2010-10-27
WO2008098979A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0510928A (pt) identificação de organismos viralmente infectados e vacinados
MY143262A (en) Roller clutch
CL2008000992A1 (es) Procedimiento para preparar compuestos derivados de ftalocianinas, naftalocianinas de silicio o germanio; propcedimientos para detectar e identifiar sustancias marcadoras en liquidos; compuestos de ftalocianinas de silicio.
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
BR112013004245A2 (pt) método, e, fluido espaçador
AR065336A1 (es) Preparacion de fluidos biologicos viralmente inactivados que tienen alta actividad de alfa -2- antiplasmina
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008003910A1 (es) Formulacion liquida, estable, conteniendo anticuerpo que comprende arginina y metionina; procedimiento para inhibir la deamidacion de moleculas de un anticuerpo que comprende agregar arginina a la formulacion liquida.
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2011001536A1 (es) Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
AR054474A1 (es) Formulacion de anticuerpos estables
AR067755A1 (es) Sistema detector microfluidico o articulo para estudiar una muestra que contiene un analito
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
BRPI0815920A2 (pt) Composto, composição farmacêutica, e, uso do composto.
CL2007000361A1 (es) Combinacion que comprende un inhibidor de la arn polimerasa del virus de la hepatitis c (vhc) y un inhibidor de la proteasa del vhc; composicion farmaceutica que la comprende; y uso de la combinacion para tratar trastornos asociados con vhc.
AR066395A1 (es) Reovirus que tienen secuencias modificadas
BR112016025253A2 (pt) misturador estático
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
ES2674177T3 (es) Preparación de suero
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal